The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-FU/LV.
 
Andrea Wang-Gillam
Consulting or Advisory Role - Merrimack; Newlink Genetics; Pfizer
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Biomed (Inst); CTI (Inst); Newlink Genetics (Inst); Pfizer (Inst); Precision Therapeutics (Inst); Verastem (Inst)
Other Relationship - Axis Pharma; Clinical Care Options; Peerview
 
Chung-Pin Li
No Relationships to Disclose
 
Gyorgy Bodoky
Consulting or Advisory Role - Bayer; Ipsen; Janssen; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Janssen; Lilly; Novartis; Pfizer; Roche
 
Andrew Dean
Honoraria - AstraZeneca; Baxalta
Consulting or Advisory Role - Baxalta
Travel, Accommodations, Expenses - Baxalta
 
Kyung-Hun Lee
Honoraria - Eisai
Consulting or Advisory Role - Novartis
 
David Cunningham
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Sanofi (Inst)
 
Richard Hubner
Consulting or Advisory Role - BTG; Celgene; Ipsen
Travel, Accommodations, Expenses - Bayer; Celgene
 
Jens T. Siveke
Honoraria - Celgene; Lilly; Merrimack
Consulting or Advisory Role - Celgene; Lilly; Merrimack
Research Funding - 4SC; Celgene
 
Fadi S. Braiteh
Honoraria - Amgen; AstraZeneca; Bayer; bioTheranostics; Boehringer Ingelheim; HERON; Incyte; Insys Therapeutics; Lilly; Merrimack; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; bioTheranostics; Boehringer Ingelheim; HERON; Incyte; Insys Therapeutics; Lilly; Merrimack; Pfizer; Roche; Sanofi
Speakers' Bureau - Amgen; AstraZeneca; Bayer; bioTheranostics; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genomic Health; Incyte; Insys Therapeutics; Ipsen; Lilly; Merck; Merrimack; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Halozyme; HERON; Incyte; Insys Therapeutics; Ipsen; Lilly; Merck; Merrimack; Pfizer; Roche; Sanofi
 
J. Marc Pipas
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
 
Bruce Belanger
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
Travel, Accommodations, Expenses - Merrimack
 
Floris de Jong
Employment - Shire
Stock and Other Ownership Interests - Shire
 
Purvi D. Mody
Employment - Clovis Oncology; Merrimack; Pfizer (I)
Stock and Other Ownership Interests - Clovis Oncology; Merrimack; Pfizer (I)
 
Li-Tzong Chen
Honoraria - Bayer; Lilly; Merck Serono; Novartis; PharmaEngine; TTY Biopharm
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MDS Nordion; Merrimack; Ono Pharmaceutical; Shire
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Polaris (Inst); Taiho Pharmaceutical (Inst); TTY Biopharm (Inst)
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Cell Therapeutics; CerRx; EmergingMed; McKesson; Medtronic; SynDevRx
Honoraria - Celgene; Cerulean Pharma; Genentech
Consulting or Advisory Role - AADi; Alethia Biotherapeutics; Alpha Cancer Technologies; Aptose Biosciences; Arsia Therapeutics; Arvinas; Bellicum Pharmaceuticals; BiolineRx; Biological Dynamics; Bionomics; Bristol-Myers Squibb; CanBas; Cavion; Cerulean Pharma; CV6 Therapeutics ; CytomX Therapeutics; CytRx Corporation; dalian wanchun biotechnology; Deciphera; DNAtrix; EMD Serono; Esperance Pharmaceuticals; Evelo Therapeutics; Five Prime Therapeutics; Formula Pharmaceuticals; Fujifilm; Gilead Sciences; HealthCare Pharmaceuticals; Histogen; Horizon Discovery; Horizon Pharma; Idera; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Inform Genomics; Innate Pharma; Insys Therapeutics; Intezyne Technologies; Kalos Therapeutics; Kinex; Kura Oncology; Lantern Pharma; Lilly; Lixte Biotechnology; MBC Pharma; Medelis; Medical Prognosis Institute; Merus; miRNA Therapeutics; Nucana; Oncolytics; Oncolyze; Pain Therapeutics; Pain Therapeutics; Pfizer; Pharmacyclics; Pharmamab; Phosplatin Therapeutics; Progen; RenovoRx; Samsung; Samumed; Senhwa Biosciences; SOTIO; Strategia Therapeutics; Sun Biopharma; Superlab Far East; Synergene; Systems Imagination; TD2; Theravance; Tolero Pharmaceuticals; Toray Industries; Trovagene; Ventana Medical Systems
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); ArQule (Inst); Baxalta (Inst); Biomarin (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); miRNA Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Strategia (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
Travel, Accommodations, Expenses - FORMA Therapeutics; Merrimack